Thrombin Activatable Fibrinolysis Inhibitor and an Antifibrinolytic Pathway
- 1 December 2000
- journal article
- review article
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 20 (12), 2511-2518
- https://doi.org/10.1161/01.atv.20.12.2511
Abstract
Abstract —Coagulation and fibrinolysis are processes that form and dissolve fibrin, respectively. These processes are exquisitely regulated and protect the organism from excessive blood loss or excessive fibrin deposition. Regulation of these cascades is accomplished by a variety of mechanisms involving cellular responses, flow, and protein-protein interactions. With respect to regulation mediated by protein-protein interaction, the coagulation cascade appears to be more complex than the fibrinolytic cascade because it has more components. Yet each cascade is regulated by initiators, cofactors, feedback reactions, and inhibitors. Coagulation is also controlled by an anticoagulant pathway composed of (minimally) thrombin, thrombomodulin, and protein C. 1 Protein C is converted by the thrombin/thrombomodulin complex to activated protein C (APC), which catalyzes the proteolytic inactivation of the essential cofactors required for thrombin formation, factors Va and VIIIa. An analogous antifibrinolytic pathway has been identified recently. This pathway provides an apparent symmetry between coagulation and fibrinolysis and is also composed of thrombin, thrombomodulin, and a zymogen that is activated to an enzyme. The enzyme proteolytically inactivates a cofactor to attenuate fibrinolysis. However, unlike APC, which is a serine protease, the antifibrinolytic enzyme is a metalloprotease that exhibits carboxypeptidase B–like activity. Within a few years of each other, 5 groups independently described a molecule that accounts for this antifibrinolytic activity. We refer to this molecule as thrombin activatable fibrinolysis inhibitor (TAFI), a name that is based on functional properties by which it was identified, assayed, and purified. (Because of the preferences of some journals “activatable” is occasionally referred to as “activable.”) This review will encompass a historical account of efforts to isolate TAFI and characterize it with respect to its activation, activity, regulation, and potential function in vivo.Keywords
This publication has 52 references indexed in Scilit:
- Plasma and Recombinant Thrombin-activable Fibrinolysis Inhibitor (TAFI) and Activated TAFI Compared with Respect to Glycosylation, Thrombin/Thrombomodulin-dependent Activation, Thermal Stability, and Enzymatic PropertiesPublished by Elsevier ,1998
- Functional Characterization of Recombinant Human Meizothrombin and Meizothrombin(desF1)Journal of Biological Chemistry, 1997
- A Steady-state Template Model That Describes the Kinetics of Fibrin-stimulated [Glu1]- and [Lys78]Plasminogen Activation by Native tissue-type Plasminogen Activator and Variants That Lack Either the Finger or Kringle-2 DomainPublished by Elsevier ,1997
- TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation and Fibrinolytic Cascades through the Thrombin-Thrombomodulin ComplexPublished by Elsevier ,1996
- Activated Human Plasma Carboxypeptidase B Is Retained in the Blood by Binding to α2-Macroglobulin and Pregnancy Zone ProteinJournal of Biological Chemistry, 1996
- Activation and Characterization of Procarboxypeptidase B from Human PlasmaBiochemistry, 1995
- Thrombin, a Link between Coagulation Activation and FibrinolysisAnnals of the New York Academy of Sciences, 1992
- An arginine specific carboxypeptidase generated in blood during coagulation or inflammation which is unrelated to carboxypeptidase N or its subunitsBiochemical and Biophysical Research Communications, 1989
- Platelet plasminogen activator inhibitor: purification and characterization of interaction with plasminogen activators and activated protein CBiochemistry, 1989
- Fibrinolysis mediated by tissue plasminogen activator. Disclosure of a kinetic transitionEuropean Journal of Biochemistry, 1985